Cerebral palsy (CP) is a group of permanent movement and posture disorders caused by brain injury before, during, or shortly after birth. Severity and type vary widely; some individuals are minimally affected, whilst others have profound motor and cognitive disability. Early intervention maximises function and independence.
Physiotherapy—stretching, strengthening, balance, gait training—is the cornerstone, begun as early as possible and continued lifelong. Occupational therapy develops self-care and fine motor skills. Speech therapy addresses swallowing and communication if affected. Muscle relaxants (baclofen, tizanidine, dantrolene sodium) and botulinum toxin injections reduce spasticity, improving comfort and function. Orthopaedic surgery corrects contractures and improves gait in selected cases. Assistive devices—walkers, wheelchairs, communication aids—enhance independence. Educational support and vocational training sustain learning and employment.
Hyperbaric oxygen therapy, stem cell tourism, and acupuncture are sought by some families; evidence is absent or contradictory. Herbal remedies and unproven supplements carry risk of delay in evidence-based care.
Stem cell therapy for CP is heavily marketed but minimally studied. Umbilical cord blood-derived cells and mesenchymal cells are being investigated for their theoretical ability to reduce brain inflammation and promote neuroplasticity. Clinical trials are few; benefit claims often exceed evidence. Regenerative approaches are not standard and carry risk of false hope and financial harm.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Physiotherapy & Gait Training | Standard | Strong | €60–100/session | Low | Ongoing; gains cumulative with consistent practice |
| Occupational Therapy | Standard | Strong | €60–100/session | Low | Ongoing; adaptive skills improve over months |
| Speech & Language Therapy | Standard | Strong | €70–110/session | Low | Ongoing; communication improves gradually |
| Botulinum Toxin Injections (Spasticity) | Standard | Strong | €800–1,500 per treatment | Low | 3–7 days to effect; lasts 12–16 weeks |
| Oral Muscle Relaxants (Baclofen, Tizanidine) | Standard | Moderate | €50–120/month | Low | Continuous; reduces stiffness and pain |
| Orthopaedic Surgery (Contracture Release, Tendon Transfer) | Standard | Strong | €10,000–25,000 | High | 6–12 weeks; improved gait and function |
| Umbilical Cord Blood Stem Cell Infusion | Regenerative | Investigational | €15,000–35,000 | Medium | 1–2 weeks; long-term motor improvement unproven |
| Assistive Devices (Walkers, Wheelchairs, Communication Aids) | Standard | Strong | €500–5,000 | Low | Immediate; independence enhanced |
Stem cell therapy is heavily promoted but minimally studied. Early work suggests mesenchymal or cord blood cells might reduce inflammation; clinical benefit is unproven. Established therapies—physio, occupational therapy, botulinum toxin, surgery—remain the evidence-based foundation.
Treatment aims to maximise function, independence, and quality of life—not to "cure" or normalise movement. Early intensive physiotherapy, management of spasticity, orthopaedic care, and assistive technology help children achieve their potential.
CP does not worsen neurologically; brain injury is permanent. However, untreated spasticity and inactivity can lead to contractures and reduced mobility. Consistent therapy prevents secondary complications and maintains function.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita